<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01499342</url>
  </required_header>
  <id_info>
    <org_study_id>BM/BOSS 02-002</org_study_id>
    <nct_id>NCT01499342</nct_id>
  </id_info>
  <brief_title>Belgian Prospective Multicentre Registry to Evaluate Safety and Performance of the Optimed Stent in the Superficial Femoral Artery</brief_title>
  <acronym>BOSS</acronym>
  <official_title>Belgian Prospective Multicentre Registry to Evaluate Safety and Performance of the Optimed Stent to Treat Atherosclerotic Lesions in the Superficial Femoral Artery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>be Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ziekenhuis Oost-Limburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>be Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Belgian prospective multicentre registry to evaluate safety and performance of the
      Sinus-Superflex-Visual stent (Optimed) in Superficial Femoral Artery (SFA) atherosclerotic
      lesions. Target number is 500 patients in approximately 11 centres. Patients will be followed
      for a period of 2 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary patency</measure>
    <time_frame>12, 24 months</time_frame>
    <description>Primary patency rate at 12 and 24 months as determined by Duplex ultrasound, defined as &lt;50% diameter restenosis(systolic velocity ratio no greater than 2.4) at the level of the treated lesion, without occurrence of target lesion revasularization between the index-procedure and the 12 and 24 months follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary patency</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Patency as defined by absence of &gt;50% restenosis , whether or not after additional intervention to maintain this patency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Target lesion revascularisation rate as defined by the number of new revascularizations (endovascular or surgery) carried out due to restenosis or thrombosis at the level of the stented lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Target vessel revascularization rate as defined by the number of new revascularizations (endovascular or surgery) carried out due to restenosis or a new stenosis in the SFA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limb-salvage rate</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success rate</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Clinical success rate defined asimprovement in symptoms according to the Rutherford classification by a minimum of 1 class.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Rutherford category 2 - 5</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Stenosis (&gt; 75%) or occlusion of the superficial femoral artery.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Stenosis (&gt; 75%) or occlusion of the superficial femoral artery (lesion up to 3 cm
             distal to Hunter's canal and 4 cm proximal to the patella)

          -  TASC II (2007)type A, B or C lesions

          -  Target vessel diameter between 4.5 and 7 mm

          -  Debilitating claudication or critical limb ischemia (Rutherford 2 to 5)

          -  At least 1 outflow vessel down to the ankle

          -  Patient is at least 18 years old

          -  Life expectancy &gt; 2 years

          -  Patient is compliant with the requested follow-up visits

        Exclusion Criteria:

          -  No informed consent

          -  Rutherford 6

          -  TASC II type D lesions

          -  Patient is not 18 years old

          -  Patient is pregnant

          -  Acute ischemia

          -  Patient is not compliant with the requested follow-up visits

          -  Unable to cross target lesion with guidewire

          -  Patient is allergic to nickel-titanium

          -  Presence of an aneurysm in the SFA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabrina Houthoofd, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Herman SchroÃ«, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziekenhuis Oost-Limburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuis Oost Limburg</name>
      <address>
        <city>Genk</city>
        <state>Limburg</state>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>December 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <name_title>be medical</name_title>
    <organization>Joris Coteur Study Coordinator</organization>
  </responsible_party>
  <keyword>Stent</keyword>
  <keyword>Atherosclerotic occlusive disease</keyword>
  <keyword>Peripheral arterial disease</keyword>
  <keyword>Superficial femoral artery</keyword>
  <keyword>SFA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

